Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Read more about Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression. Read more about Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.
Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities. Read more about Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities.
A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. Read more about A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy.
Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Read more about Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence.
Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer. Read more about Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer.
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Read more about Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
Toward a better understanding of T cells in cancer. Read more about Toward a better understanding of T cells in cancer.
Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Read more about Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy.
Stepwise evolution of therapy resistance in AML. Read more about Stepwise evolution of therapy resistance in AML.
